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Background. Nonalcoholic steatohepatitis (NASH) encompasses a histological spectrum ranging 
from simple steatosis to steatosis plus necroinflammation. It affects 3-5% of general adult 
population. NASH is associated with an increased risk of developing cirrhosis/end-stage liver 
disease, diabetes and cardiovascular disease (CVD); the correlation of liver histology in NAFLD 
with the severity of early atherosclerosis and with the impairment in glucose metabolism suggests 
the same molecular mechanisms may underlie  liver injury, diabetes and atherogenesis.  The 
knowledge of such mechanism(s) would help select NASH subjects at greater risk of cardio-
metabolic and liver-related complications for early specific interventions and tight monitoring. 
Lectin-like oxidized LDL receptor-1 (LOX-1) has been connected to cardiovascular risk in the 
general population and to insulin resistance in experimental models. Several LOX-1 functional 
single nucleotide polymorphisms (SNPs) have been recently linked to CVD susceptibility in 
humans. The IVS4-14 A>G SNP is one of these functional SNPs. 
Objective. To assess the impact of the common functional IVS4-14 A>G LOX-1 polymorphism on 
liver disease, cytokines, lipoprotein metabolism and glucose homeostasis in NASH. 
Methods. Forty nonobese, nondiabetic, normolipidemic biopsy-proven NASH patients and 40 age, 
sex, BMI and IVS4-14 A>G LOX-1 polymorphism-matched healthy controls underwent an oral fat 
load test (OFT), with measurement of plasma triglyceride-rich lipoprotein subfractions,  oxidized 
LDL, total antioxidant status (TAS), adipokines, and cytokeratin-18 fragments (marker of 
hepatocyte apoptosis).  Subjects underwent also an oral glucose tolerance test (OGTT), with 
Minimal Model analysis to yield parameters of glucose homeostasis. 
Results. LOX-1 polymorphism was independently associated with liver histology (with  G allele 
carriers having a more severe liver disease); during the OFT, the G allele was associated with small 
triglyceride-rich lipoprotein accumulation, lower TAS levels, adipokine imbalance (higher resistin 
and lower adiponectin) and increased cytokeratin-18 fragments. 
Conclusions. We provided evidence that the LOX-1 IVS4-14 A>G SNP was independently 
associated with the severity of liver disease in NASH, even after adjustment for adipokines and 
other confounders, suggesting LOX-1 function may directly modulate liver disease progression in 
NASH. LOX-1 IVS4-14 A>G SNP may be the connection among liver injury, diabetes and CVD in 
NASH. Further in vitro and adequately-powered prospective studies need to elucidate underlying 
mechanisms and to assess the usefulness of LOX-1 IVS4-14 A>G SNP for screening and treatment 
of patients at higher liver-related, metabolic and cardiovascular risk. 
 
